The aim of this study has been to evaluate the use of synthetic Prostacyclin in Progressive Systemic Sclerosis. 14 patients suffering from PSS were treated with an analogue of PGI2 for 3 weeks. Subjective and objective parameters have been analyzed. Most of the patients presented a reduction of vasospastic symptomatology and of other aspects of the disease. We believe that these data have to be confirmed by other studies.
|Translated title of the contribution||The use of synthetic prostacyclin in progressive systemic sclerosis|
|Number of pages||7|
|Publication status||Published - 1994|
ASJC Scopus subject areas